Printed From:

Hypothetical patient profile. Individual results may vary.

In this pharmacokinetics /
pharmacodynamics study,
Toujeo® demonstrated a
glucose-lowering effect
that lasted up to 36 hours1

Consistent blood
glucose levels within
the
ADA-recommended
range of 80-130 mg/dL1-3

ADA, American Diabetes Association; BG, blood glucose; GIR, glucose infusion rate; PD, pharmacodynamics; PK, pharmacokinetics; T1DM, type 1 diabetes mellitus.

Significant A1C reductions in a broad range of patients

Select a patient with Type 1 or Type 2 Diabetes below to see efficacy and safety results from the 4 EDITION clinical studies

EDITION 3: T2DM, Insulin-naive patients with noninsulin antidiabetic drugs1,4

Meet Ray, a 48-year-old insulin-naive patient with T2DM, who plays guitar for a jazz band and is constantly on the go. He was concerned about how adding another medication would affect his busy lifestyle.

x

*There were no clinically important differences in body weight between treatment groups.1

FPG, fasting plasma glucose; OADs, oral antidiabetic drugs; T2DM, type 2 diabetes mellitus.
aModified intent to treat population.
bSevere hypoglycemia: an event requiring assistance of another person to actively administer a resuscitative action.
cDocumented symptomatic hypoglycemia: an event with typical symptoms of hypoglycemia accompanied by a self-monitored plasma glucose value ≤54 mg/dL.

EDITION 2: T2DM, Basal insulin switch patients1,6,7

Previously on basal insulin and oral antidiabetic drugs with noninsulin antidiabetic drugs

Meet Sofia, a 46-year-old T2DM patient with commercial insurance. She works all week and teaches salsa dancing on the weekends. She was having trouble getting to goal on a basal insulin and OADs.

x

*There were no clinically important differences in body weight between treatment groups.1

FPG, fasting plasma glucose; OADs, oral antidiabetic drugs; T2DM, type 2 diabetes mellitus.
aModified intent to treat population.
bSevere hypoglycemia: an event requiring assistance of another person to actively administer a resuscitative action.
cDocumented symptomatic hypoglycemia: an event with typical symptoms of hypoglycemia accompanied by a self-monitored plasma glucose value ≤54 mg/dL.

EDITION 1: T2DM, Basal insulin switch patients + mealtime1,8,9

Previously on basal and mealtime insulin ± metformin

Meet Frank, a 64-year-old T2DM patient with commercial insurance. He is a security guard by day and trumpet player by night. He wasn’t reaching his glycemic goal on Lantus® 60 Units and mealtime insulin

x

* There were no clinically important differences in body weight between treatment groups.1

FPG, fasting plasma glucose; OADs, oral antidiabetic drugs; T2DM, type 2 diabetes mellitus.
aModified intent to treat population.
bSevere hypoglycemia: an event requiring assistance of another person to actively administer a resuscitative action.
cDocumented symptomatic hypoglycemia: an event with typical symptoms of hypoglycemia accompanied by a self-monitored plasma glucose value ≤54 mg/dL.

EDITION 4: T1DM1,10,11

Previously on basal and mealtime insulin with mealtime insulin analog

Meet Meg, a 22-year-old with T1DM. She is concerned about how administering basal insulin will fit into her highly active life as a classical music professional

x

*There were no clinically important differences in body weight between treatment groups.1

FPG, fasting plasma glucose; OADs, oral antidiabetic drugs; T2DM, type 2 diabetes mellitus.
aModified intent to treat population.
bSevere hypoglycemia: an event requiring assistance of another person to actively administer a resuscitative action.
cDocumented symptomatic hypoglycemia: an event with typical symptoms of hypoglycemia accompanied by a self-monitored plasma glucose value ≤54 mg/dL.

Toujeo®: reduced injection volume, smaller precipitate, and gradual insulin release1,12

Toujeo®—a different formulation from Lantus®

HOW TOUJEO® WORKS−A Dynamic Look at the Mechanism of Action of Toujeo®

This video highlights the formulation differences between Toujeo® and Lantus®.

 

Play

 

Clinical Trials

Read about the 4 EDITION clinical trials at PubMed.gov

Read more

Dosing and Administration

Learn about how to get your patients started on Toujeo®

Learn more

References: 1. Toujeo Prescribing Information. 2. Becker RHA, Dahmen R, Bergmann K, Lehmann A, Jax T, Heise T. Diabetes Care. 2015;38(4):637-643. 3. American Diabetes Association. Diabetes Care. 2017;40(suppl 1):S1-S135. 4. Data on file (CSR EDITION 3), Sanofi US. 5. Bolli GB, Riddle MC, Bergenstal RM, et al; the EDITION 3 study investigators. Diabetes Obes Metab. 2015;17(4):386-394. 6. Data on file (CSR EDITION 2), Sanofi US. 7. Yki-Järvinen H, Bergenstal R, Ziemen M, et al; the EDITION 2 study investigators. Diabetes Care. 2014;37(12):3235-3243. 8. Data on file (CSR EDITION 1), Sanofi US. 9. Riddle MC, Bolli GB, Ziemen M, et al; the EDITION 1 study investigators. Diabetes Care. 2014;37(10):2755-2762. 10. Home PD, Bergenstal RM, Bolli GB, et al; the EDITION 4 study investigators. Diabetes Care. 2105;38(12):2217-2225. 11. Data on file (CSR EDITION 4), Sanofi US. 12. Maiorino Ml, Petrizzo M, Capuano A, Giugliano D, Esposito K. Exp Opin Ther. 2014;14(6):799-808.